文献速递乳腺癌放疗放疗物理与技术

乳房切除术后放疗联合或未联合植入物重建在临床靶区覆盖和生存方面均安全:一项匹配队列研究

Post-mastectomy radiation therapy with or without implant-based reconstruction is safe in terms of clinical target volume coverage and survival - A matched cohort study.
PubMed 文献 · Radiother Oncol · 2018-07-25

本匹配队列研究纳入128例植入物即刻乳房重建(IBR+)和252例未重建(IBR-)乳腺癌患者,比较放疗靶区覆盖及复发生存。IBR+组将植入物从CTV中排除后,无淋巴结照射患者V95%均值IBR+组84%对IBR-组92%。中位随访5.8年,两组复发率、无复发生存、总生存和乳腺癌特异性生存均无统计学显著差异。

要点

  • IBR+组将植入物从CTV中排除后,无淋巴结照射患者V95%均值84%对IBR-组92%,存在轻度低剂量。
  • 中位随访5.8年,IBR+与IBR-组复发率、无复发生存、总生存和乳腺癌特异性生存均无统计学显著差异。
  • 作者认为本机构所用整体治疗方案是安全的,但承认因植入物存在时皮下组织投影导致靶区轻度低剂量。

核心结论

  • 乳房切除术后放疗联合植入物重建导致靶区轻度低剂量,原因是植入物存在时皮下组织的投影。
  • IBR+与IBR-患者复发率和生存率分布均等,表明本机构所用整体治疗方案是安全的。

研究设计与样本

  • 匹配队列研究,纳入128例植入物即刻乳房重建(IBR+)患者和252例未重建(IBR-)对照患者,对肿瘤分期和治疗等潜在混杂效应进行了控制。

主要发现

  • 无淋巴结照射患者中,减去植入物后的CTV V95%均值IBR+组为84%,IBR-组为92%。
  • 中位随访5.8年(范围0.1-7.5年),IBR+与IBR-组复发率比、无复发生存(log-rank p=0.142)、总生存(log-rank p=0.096)和乳腺癌特异性生存(log-rank p=0.147)均无统计学显著差异。

关键数值与推荐

  • IBR+患者放疗计划图像中将植入物体积从CTV中排除,靶区覆盖以V95%(CTV被≥95%等剂量线覆盖)评估。
  • 无淋巴结照射患者V95%均值:IBR+组84%对IBR-组92%。

临床怎么用

  • 原文结论认为本机构所用整体治疗方案是安全的,未给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Patients with breast cancer receiving mastectomy in our institution are offered immediate breast reconstruction (IBR). IBR may have an impact on the optimisation of radiation therapy (RT). Therefore, we aimed to evaluate the clinical target volume (CTV) dose coverage when disregarding the dose received by the breast implant in women treated for breast cancer. Furthermore, to investigate the safety of immediate breast reconstruction (IBR) with an implant (IBR+) in terms of recurrence and survival compared to patients without an implant (IBR-). PATIENTS AND METHODS: This matched-cohort included 128 patients with IBR+ and 252 IBR- patients (controls). The potential confounding effects of tumour stage and treatment were controlled for. For IBR+ patients, the implant volume was excluded from the CTV in the RT planning images, and the RT target coverage (V95%: CTV covered by ≥the 95% isodose) was compared between the IBR+ and IBR- groups. RESULTS: A limited under dosage was observed in patients without lymph-node irradiation; the V95% mean values for the CTV subtracting the implant were 84% and 92%, for IBR+ and IBR- groups, respectively. Median follow-up duration was 5.8 years (0.1-7.5 years). In comparing IBR+ and IBR- groups, no statistically significant differences were found in the incidence of recurrence rate ratios or recurrence free survival (log-rank p = 0.142), overall survival (log-rank p = 0.096), or breast cancer specific survival (log-rank p = 0.147). CONCLUSIONS: Post-mastectomy radiation therapy and implant-based reconstruction lead to minor under dosage of the target, due to the projection of the subcutaneous tissue in the presence of the implant. However, recurrence and survival rates were equally distributed among IBR+ and IBR- patients indicating that the overall treatment protocol used in our institution is safe.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Bjöhle J, Onjukka E, Rintelä N, et al. Post-mastectomy radiation therapy with or without implant-based reconstruction is safe in terms of clinical target volume coverage and survival - A matched cohort study. Radiother Oncol. 2018. PMID: 30055939. doi:10.1016/j.radonc.2018.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。